Short answer
Compass Therapeutics, Inc. (CMPX) filed an 8-K current report with the SEC on September 22, 2026 reporting Item 7.01 (Regulation FD Disclosure). Management signals tovecimig’s potential use in second-line BTC treatment.
Compass Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Management signals tovecimig’s potential use in second-line BTC treatment
- FDA discussions planned before a potential BLA submission for COMPANION-002 data
- Complete COMPANION-002 dataset expected at a medical conference this year
- Additional funding required to advance development and business plans
- Approval timing and pathway remain uncertain, with standard clinical and regulatory risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Compass Therapeutics, Inc. 8-K filings
Get the next CMPX 8-K as it lands
Follow CMPX for push alerts, or ask the research agent what this filing means.